NCT06709040Enrolling by invitation
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
A Non-interventional, Observational, Registry-based Study to Investigate Long-term Safety and Clinical Parameters of Somapacitan Treatment in Paediatric Patients With Growth Hormone Deficiency During Routine Clinical Practice
Source: ClinicalTrials.gov · Last updated 6 Apr 2026
Brief summary (registry, in English)
The aim of this study is to look at the long-term safety and clinical parameters of somapacitan in paediatric participants with growth hormone deficiency under routine clinical practice conditions. The study population will include 400 paediatric growth hormone deficient participants from the Global Registry for Novel Therapies in Rare Bone and Endocrine Conditions (GloBE-Reg) treated with once-weekly somapacitan and fulfilling the eligibility criteria of the study. The total duration of the study is planned to 10 years consisting of a 5-year recruitment period in the GLoBE-Reg followed by a 5-year follow-up period.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 26 Nov 2024
- Start date
- 13 Dec 2024
- Primary completion date
- 14 Apr 2034
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Childhood cancers, Type 2 diabetes
- NCT number
- NCT06709040
What you commit to
- Study type: Observational
- Planned participants: 500
- From 13 Dec 2024 to the primary completion date, 14 Apr 2034
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants with active malignancy or in treatment for active pre-existing malignancy.
Who the study is looking for
- Treated with commercially available somapacitan according to local practice at the discretion of the physician.
- Primary confirmed diagnosis of growth hormone deficiency as per local practice.
- Male or female below 18 years of age at the time of signing informed consent in the GLoBE-Reg.
Age in the registry: - to 18 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Glasgow Coordinator of this site? Confirm its status | Glasgow | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.